Pros: - Richard met with tier 1 diagnostics groups in the US for the US roll-out - News due in 'the coming weeks' around Mexico and Spain roll out - Janseen collaboration going as planned, reiterating the potential use of PD every time Gliflozin is prescribed. - FY19 receipts were $1.7M, more than double PY - Upcoming $1.1m in R&D rebate to further strength cash position which is currently at $1.5M
Cons: - Endometrosis POC delayed due to mass spectrometry machine failure - Giardia POC now in a second POC stage? didnt' know 2 POC's were required.. - Dominican Republic royalties either not included or was minuscule - Quarterly receipts only $245k
Overall pretty good just a dam shame we are taking so long to commercialize PromarkerD considering it was ready nearly 2 years ago. One can dream but imagine what this means for us if we partner with a tier1 diagnostics group in the U.S and the Jannsen collaboration goes according to plan? Good luck guys and look forward to every one else thoughts on the quarterly.
PIQ Price at posting:
35.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)